KVUE NYSE
Credit Risk of going bust: lower than 81% of companies Debt: 18.5% of company value Bonds: $77.3M held by 211 funds, 51 bp over Treasuries → details ▾
If the stock fell to about $0.28 (down 99%), Kenvue Inc. would be worth roughly what it owes.
Total debt $8.48B against a stock market value of $37.32B.
Distance to default 9.99 (Merton model): prices to 2026-10-27, balance sheet 2026-06-28, debt counted $4.94B (short-term plus half of long-term), stock volatility 24.4%; Altman Z 2.28. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Summit, NJ 07901
US
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lawson Carlton | A-Award | 36,597 | $17.20 | 2026-10-02 |
| Orlando Matthew | A-Award | 35,754 | $17.20 | 2026-10-02 |
| Orlando Matthew | F-InKind | 14,749 | $17.20 | 2026-10-02 |
| Stevens Meredith | A-Award | 35,754 | $17.20 | 2026-10-02 |
| Stevens Meredith | F-InKind | 15,192 | $17.20 | 2026-10-02 |